A Comparison of Seroquel Vs. Risperidone in Schizophrenia

This study has been completed.

First Received: May 2, 2002 Last Updated: June 23, 2005 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00034905

Purpose

The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.

Condition	Intervention	Phase
Schizophrenia	Drug: quetiapine fumarate vs risperidone	Phase IV

Study Type:	Interventional
Study Design:	Treatment

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Risperidone Quetiapine Quetiapine fumarate

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Male / Female, 18-65 years old
Schizophrenia (as per DSM IV)

Exclusion Criteria

Concurrent use of psychotropic medication
Does not fulfill moderately ill on CGI

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034905

Show 64 Study Locations

Sponsors and Collaborators

AstraZeneca

More Information

No publications provided

Study ID Numbers:	5077US/0043
Study First Received:	May 2, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00034905 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions

Schizophrenia
Quetiapine
Serotonin Antagonists
Serotonin Agents
Mental Disorders
Therapeutic Uses
Dopamine Agents
Central Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 09, 2009